A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder

Objectives: In a previous pivotal study of children and adolescents (aged 6–17 years) with attention-deficit/hyperactivity disorder (ADHD), dose-optimized SHP465 mixed amphetamine salts (MAS) extended-release (12.5–25 mg once daily) was superior to placebo in reducing ADHD symptoms. This study evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattingly, Greg, Arnold, Valerie, Yan, Brian, Yu, Ming, Robertson, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698843/
https://www.ncbi.nlm.nih.gov/pubmed/33185468
http://dx.doi.org/10.1089/cap.2020.0005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698843/
https://www.ncbi.nlm.nih.gov/pubmed/33185468
http://dx.doi.org/10.1089/cap.2020.0005

Ejemplares similares